HR+ HER2-

An overview of breast cancer treatment options

The medical terms used in breast cancer treatment options can be confusing to understand, especially when you’re first navigating your diagnosis. To help you navigate the different treatment options, Dr. Pooja Advani, a breast medical oncologist at Mayo Clinic, provides a patient-friendly explanation of the major treatment types and breaks down how they work, who they work best for, and the potential side effects.

HR+ breast cancer study reveals help for severe hot flashes

For women with hormone receptor-positive (HR+) breast cancer or women who are at high risk for breast cancer, endocrine therapy is often recommended by their care team as part of their approach to treatment. Hot flashes and night sweats (also known as vasomotor symptoms) are common side effects of endocrine therapy, which can not only complicate treatment but also diminish quality of life.

What every hormone positive survivor should know

Could my cancer still come back? You finish treatment. You count the years. You start to breathe again. And then, out of nowhere, the cancer shows up again. Not in your breast. Maybe not even in your chest area. But in your bones, your liver, your lungs. It’s called late recurrence, and for many people, it’s an ongoing concern.

Managing neck pain in HR+, HER2- breast cancer

Why does neck pain happen during breast cancer treatment? When you’re going through treatment for HR-positive/HER2-negative breast cancer, you might experience neck pain. Many women with breast cancer find that side effects like muscle pain, joint pain, and stiffness make daily activities more difficult.

Exploring tests for breast cancer patients: Oncotype DX and beyond

What tests are available for breast cancer patients? We were fortunate to host Dr. Sara Hurvitz, a medical oncologist and clinical research leader at Fred Hutch, as part of our "Ask the Expert" webinar series. Dr. Hurvitz led a deep dive into important advancements in breast cancer testing that all patients should know.

Is TRUQAP Chemo? How It Works & FAQs

TRUQAP (capivasertib) is used with Fulvestrant to treat hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer that has worsened or returned within 12 months.

What you need to know about CDK 4/6 inhibitors in early-stage breast cancer

CDK 4/6 inhibitors have received attention for their role in treating early-stage breast cancer. The FDA recently expanded the indication for Verzenio and positive results from phase III trials were announced.

3 advancements that may impact your treatment plan in the new era of endocrine therapy for breast cancer

Endocrine therapy treatment for early-stage HR+ breast cancer is witnessing significant advances, moving towards more tailored treatments that could improve outcomes for high-risk patients and deescalate treatment recommendations for low and intermediate-risk ones.

Newsflash: First Oral SERD Orserdu (elacestrant) FDA-Approved

If you were diagnosed with ER-positive, HER2-negative metastatic breast cancer, Outcomes4Me has a team of oncology nurse practitioners ready to consult with you regarding this new therapy.

What Is Endocrine Therapy For Breast Cancer?

Endocrine therapy is aimed at stopping cancer growth that is affected by hormones. It is commonly referred to as hormone therapy.